Scrip is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction
Brought to you by

Mesoblast partners stem cell drugs exclusively with Cephalon

Executive Summary

Australian regenerative medicine firm Mesoblast Ltd. has licensed Cephalon Inc. exclusive global rights to therapeutics derived from adult mesenchymal precursor stem cells (MPCs) for degenerative neurological and cardiovascular diseases including congestive heart failure, acute myocardial infarction, angina, peripheral vascular disease/critical limb ischemia, Parkinson's, stroke, multiple sclerosis, Huntington's, and Alzheimer's. The deal will also include cell products that expand hematopoietic stem cell (bone marrow) transplants for blood cancer patients.
Deal Industry
  • Biotechnology
    • Gene Therapy, Cell Therapy
  • Pharmaceuticals
    • Specialty Pharmaceuticals
Deal Status
  • Final
Deal Type
  • Alliance
    • R+D and Marketing-Licensing
    • Includes Equity
    • Intra-Biotech Deal
    • Includes Contract

Related Companies

Advertisement
UsernamePublicRestriction

Register